| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/SJ.KI.5002195 |
| P8608 | Fatcat ID | release_c5xdosvdajg2nbbci47zzh5skq |
| P698 | PubMed publication ID | 17361112 |
| P5875 | ResearchGate publication ID | 6446347 |
| P50 | author | Jong Eun Lee | Q38323530 |
| Dong-Ryeol Ryu | Q43973018 | ||
| P2093 | author name string | Kim HJ | |
| Kim JJ | |||
| Han SH | |||
| Kim JS | |||
| Han DS | |||
| Kang SW | |||
| Choi HY | |||
| Jung DS | |||
| Kwak SJ | |||
| Li JJ | |||
| Yoo TH | |||
| P2860 | cites work | Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition | Q28215181 |
| Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli | Q28565628 | ||
| High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells | Q28568580 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| AT(1) and AT(2) receptors in the kidney: role in disease and treatment. | Q30306077 | ||
| ANG II type 2 receptor regulates smooth muscle growth and force generation in late fetal mouse development | Q30434317 | ||
| Update on the role of the AT2 receptor | Q30435327 | ||
| Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats | Q31063566 | ||
| Activation of a local tissue angiotensin system in podocytes by mechanical strain | Q33195945 | ||
| Role of angiotensin II in diabetic nephropathy. | Q34039750 | ||
| Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose | Q34573082 | ||
| Podocyte biology and the emerging understanding of podocyte diseases | Q35198433 | ||
| Podocyte loss and progressive glomerular injury in type II diabetes | Q37362675 | ||
| Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention | Q38623177 | ||
| A quantitative immunofluorescence study of glomerular cell adhesion proteins in proteinuric states | Q39458149 | ||
| Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. | Q39645421 | ||
| The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy | Q40205911 | ||
| Characterization of angiotensin II-receptor subtypes in podocytes | Q40611479 | ||
| Effect of glucose on the expression of the angiotensinogen gene in opossum kidney cells | Q41065781 | ||
| Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. | Q41084039 | ||
| The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms | Q41323510 | ||
| Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium | Q41581730 | ||
| Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension | Q43709059 | ||
| Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade | Q43709062 | ||
| Podocyte number in normotensive type 1 diabetic patients with albuminuria | Q44155574 | ||
| Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells | Q44217757 | ||
| Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose | Q44378900 | ||
| Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy | Q44378923 | ||
| ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy | Q44475434 | ||
| Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease | Q44486184 | ||
| Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial | Q44526964 | ||
| Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. | Q44669218 | ||
| Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. | Q45000528 | ||
| P-Cadherin is decreased in diabetic glomeruli and in glucose-stimulated podocytes in vivo and in vitro studies. | Q45221667 | ||
| A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli | Q45258260 | ||
| Functional expression of the renin-angiotensin system in human podocytes | Q46724544 | ||
| Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C | Q69059319 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation | Q73060915 | ||
| Glomerular cell number in normal subjects and in type 1 diabetic patients | Q73942888 | ||
| Urinary excretion of podocytes in patients with diabetic nephropathy | Q74291207 | ||
| Angiotensin II modulates cellular functions of podocytes | Q77295873 | ||
| The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology | Q78461702 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1019-1027 | |
| P577 | publication date | 2007-03-14 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Activation of the renin-angiotensin system within podocytes in diabetes | |
| P478 | volume | 71 |
| Q37190244 | 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway |
| Q34455455 | Activation of NFAT signaling in podocytes causes glomerulosclerosis |
| Q46794009 | Activation of a local renin angiotensin system in podocytes by glucose |
| Q46250380 | Activation of renal renin-angiotensin system in upstream stimulatory factor 2 transgenic mice |
| Q83835489 | Activation of skin renin-angiotensin system in diabetic rats |
| Q85195034 | Adenosine A(2B) receptor-mediated VEGF induction promotes diabetic glomerulopathy |
| Q50475761 | Albumin inhibits the insulin-mediated ACE2 increase in cultured podocytes. |
| Q33999815 | Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus |
| Q37277601 | Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy |
| Q46356625 | Angiotensin II regulates collagen metabolism through modulating tissue inhibitor of metalloproteinase-1 in diabetic skin tissues |
| Q53254924 | Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies. |
| Q36374983 | Changes of urinary angiotensinogen concentration and its association with urinary proteins in diabetic rats |
| Q36924964 | Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase |
| Q43150818 | Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes |
| Q46543744 | Feasibility of fluorescence energy transfer system for imaging the renoprotective effects of aliskiren in diabetic mice |
| Q34283151 | Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species--ERK/JNK pathways |
| Q90632374 | Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease |
| Q42873491 | Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters |
| Q35850260 | Intracardiac intracellular angiotensin system in diabetes |
| Q53435442 | Local kallikrein-kinin system is involved in podocyte apoptosis under diabetic conditions. |
| Q37337349 | Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist |
| Q41813557 | Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells |
| Q42434881 | Mesangial cells are responsible for orchestrating the renal podocytes injury in the context of malignant hypertension |
| Q48659334 | NMDA receptors participate in the progression of diabetic kidney disease by decreasing Cdc42-GTP activation in podocytes |
| Q46346105 | Na+,K+-ATPase is modulated by angiotensin II in diabetic rat kidney--another reason for diabetic nephropathy? |
| Q37702782 | New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease |
| Q38458152 | Podocyte directed therapy of nephrotic syndrome-can we bring the inside out? |
| Q37881701 | Podocyte dysfunction in aging--related glomerulosclerosis |
| Q42258796 | Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice |
| Q45713726 | Podocytes of AT2 receptor knockout mice are protected from angiotensin II-mediated RAGE induction |
| Q37629199 | ROCK/NF-κB axis-dependent augmentation of angiotensinogen by angiotensin II in primary-cultured preglomerular vascular smooth muscle cells |
| Q48131156 | Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus |
| Q57825276 | Recent Progress in the Pathogenesis of Nephrotic Proteinuria |
| Q46301431 | Regression of glomerular injury by losartan in experimental diabetic nephropathy. |
| Q34203622 | Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade |
| Q52651166 | Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease. |
| Q38262105 | Renin-angiotensin system within the diabetic podocyte |
| Q92536780 | Role of Podocyte Injury in Glomerulosclerosis |
| Q35159588 | Role of the USF1 transcription factor in diabetic kidney disease |
| Q36175799 | Role of upstream stimulatory factor 2 in diabetic nephropathy |
| Q60484091 | Sex dimorphism in ANGII-mediated crosstalk between ACE2 and ACE in diabetic nephropathy |
| Q36936570 | Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. |
| Q37344225 | The importance of the intrarenal renin-angiotensin system |
| Q38010459 | The intracrine renin-angiotensin system |
| Q48649007 | The locally activated renin-angiotensin system is involved in albumin permeability in glomerular endothelial cells under high glucose conditions. |
| Q83179650 | The renin inhibitor aliskiren attenuates high-glucose induced extracellular matrix synthesis and prevents apoptosis in cultured podocytes |
| Q37838893 | The role of metabolic and haemodynamic factors in podocyte injury in diabetes |
| Q53669187 | Translationally controlled tumour protein is associated with podocyte hypertrophy in a mouse model of type 1 diabetes. |
| Q39676702 | Urinary angiotensin converting enzyme 2 is strongly related to urinary nephrin in type 2 diabetes patients |
| Q34416954 | Urinary angiotensinogen and urinary sodium are associated with blood pressure in normoalbuminuric children with diabetes |
| Q36236725 | Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes |
| Q37319731 | Vitamin D and diabetic nephropathy |
| Q36426113 | Vitamin D receptor signaling in podocytes protects against diabetic nephropathy |
| Q37230136 | Vitamin D receptor signaling in renal and cardiovascular protection |
Search more.